A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody–drug conjugate, in patients with advanced or metastatic cancer
Christian Kollmannsberger, Carolyn D. Britten, Anthony J. Olszanski, Joan Andrews Walker, Wei Zang, Melinda D. Willard, David B. Radtke, Daphne L. Farrington, Katherine M. Bell‐McGuinn, Amita Patnaik
Topics & Concepts
MedicineTolerabilityAdverse effectInternal medicineToxicityCancerRadioimmunotherapyAntibody-drug conjugatePhases of clinical researchGastroenterologyAntibodyOncologyPharmacologyMonoclonal antibodyImmunologyFibroblast Growth Factor ResearchBladder and Urothelial Cancer TreatmentsUrinary and Genital Oncology Studies